Dose Level 3

WITHDRAWN · PHASE1 · Lymphoma, Myeloma, Solid Tumors, Sarcoma, Kidney Cancer

The study was revised into two separate protocols to separate treatments. We will submit as separate studies.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.